Skip to main content

Clinical trial EZH-202

A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma

Organ Tissus mous
Trial status Trial open for recruitment
Trial type
Interventional with experimental drug
Phase Trial phase 2
Academic trial Non
Sponsor Epizyme
EudraCT Identifier 2015-002469-41
Inclusion criteria after standard therapy
Last update